| Description | Ensituximab (NEO-102) is a quasi-selective IgG1 monoclonal antibody against the MUC5AC variant with anti-tumour activity that inhibits colorectal and pancreatic cancer. |
| In vitro | Ensituximab (NEO-102) 是一种新型嵌合单克隆抗体，靶向 MUC5AC 的糖基化变体，对结直肠癌和胰腺癌具有特异性。临床前数据表明，ensituximab 仅靶向 MUC5AC 阳性肿瘤，而在非恶性组织中保留 MUC5AC 抗原[2]。 |
| Synonyms | NPC-1C, NEO-102, NEO-101 |
| molecular weight | N/A |
| CAS | 1092658-06-4 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Julian A Marin-Acevedo, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol. 2018 Jan 12;11(1):8. 2. Richard D Kim, et al. Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clin Cancer Res. 2020 Jul 15;26(14):3557-3564. |